Laurantis Pharma, a Turku, Finland-based privately held clinical-stage biotechnology company, has completed a €5.64m (approximately US$7.02m) funding.
Backers include Broadview Ventures, Inveni Capital, Aloitusrahasto Vera, Helsinki University Funds, and Veritas.
The company intends to use the capital for the first human trial for Lymfactin, which is a treatment for breast cancer-associated lymphedema. It uses an adenoviral vector to deliver vascular endothelial growth factor (VEGF-C) during transplantation of lymph nodes in order to avoid lymphedema.
Led by Riku Rautsola, CEO, Laurantis also develops proprietary and patent-protected formulations and applications of cis-urocanic acid, a locally acting anti-inflammatory and anti-proliferative agent for the treatment of Atopic Dermatitis, Dry Eye, Interstitial Cystitis, and Bladder Cancer.